helping patients with a rare kidney disease get phosphorous levels under control faster with Fosrenol
When I was at MicroMass I helped develop a program to promote Fosrenol as a first-line treatment for hypophosphatemia, to get dangerous phosphorous levels under control faster than other treatments.
To promote Fosrenol's competitive efficacy, we developed trade posters, banners and online material for an idea we called "The Fosrenol 14-Day Advantage." The people who need Fosrenol are end-stage kidney disease patients; time is not on their side. We felt it was crucial to get the message across in a dramatic way, which led to developing "poster" art that would grab the attention of physicians.
To promote Fosrenol's competitive efficacy, we developed trade posters, banners and online material for an idea we called "The Fosrenol 14-Day Advantage." The people who need Fosrenol are end-stage kidney disease patients; time is not on their side. We felt it was crucial to get the message across in a dramatic way, which led to developing "poster" art that would grab the attention of physicians.
